Education
About Us
Working with TipRanks
Follow Us
Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
RESEARCH TOOLSreports
Total Valuation
Scinai Immunotherapeutics has a market cap or net worth of $2.36M. The enterprise value is $8.60M.
Market Cap$2.36M
Enterprise Value$8.60M
Share Statistics
Scinai Immunotherapeutics has 933,679 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding933,679
Owned by Insiders7.40%
Owned by Institutions<0.01%
Financial Efficiency
Scinai Immunotherapeutics’s return on equity (ROE) is 1.42 and return on invested capital (ROIC) is -60.39%.
Return on Equity (ROE)1.42
Return on Assets (ROA)-0.37
Return on Invested Capital (ROIC)-60.39%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee0.00
Profits Per Employee-209.68K
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Scinai Immunotherapeutics is >-0.01. Scinai Immunotherapeutics’s PEG ratio is <0.01.
PE Ratio>-0.01
PS Ratio0.00
PB Ratio>-0.01
Price to Fair Value>-0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio<0.01
Income Statement
In the last 12 months, Scinai Immunotherapeutics had revenue of 0.00 and earned -6.50M in profits. Earnings per share was -16.64.
Revenue0.00
Gross Profit0.00
Operating Income-9.71M
Pretax Income-6.50M
Net Income-6.50M
EBITDA-9.19M
Earnings Per Share (EPS)-16.64
Cash Flow
In the last 12 months, operating cash flow was -6.48M and capital expenditures -240.00K, giving a free cash flow of -6.73M billion.
Operating Cash Flow-6.48M
Free Cash Flow-6.73M
Free Cash Flow per Share-7.21
Dividends & Yields
Scinai Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change-40.56%
50-Day Moving Average2.91
200-Day Moving Average3.44
Relative Strength Index (RSI)57.99
Average Volume (3m)23.36K
Important Dates
Scinai Immunotherapeutics upcoming earnings date is May 29, 2025, TBA Not Confirmed.
Last Earnings DateNov 22, 2024
Next Earnings DateMay 29, 2025
Ex-Dividend Date―
Financial Position
Scinai Immunotherapeutics as a current ratio of 3.06, with Debt / Equity ratio of 12.27%
Current Ratio3.06
Quick Ratio3.06
Debt to Market Cap3.33K
Net Debt to EBITDA-1.71
Interest Coverage Ratio30.65K
Taxes
In the past 12 months, Scinai Immunotherapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Scinai Immunotherapeutics EV to EBITDA ratio is -1.96, with an EV/FCF ratio of -1.80.
EV to Sales0.00
EV to EBITDA-1.96
EV to Free Cash Flow-1.80
EV to Operating Cash Flow-1.92
Balance Sheet
Scinai Immunotherapeutics has $1.03M in cash and marketable securities with $20.63M in debt, giving a net cash position of $195.00K billion.
Cash & Marketable Securities$1.03M
Total Debt$20.63M
Net Cash$195.00K
Net Cash Per Share$0.21
Tangible Book Value Per Share-$11.70
Margins
Gross margin is -91.37%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-91.37%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Scinai Immunotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―